|
1114
|
Vivotif
|
Typhoid
|
Salmonella typhi
|
Live attenuated
|
Crucell Switzerland LTD
|
Approved
|
Oral
|
NA
|
NA
|
|
1115
|
Vivotif
|
Typhoid
|
Salmonella typhi
|
Live attenuated
|
Emergent Travel Health Inc.
|
Approved
|
Oral
|
NA
|
NA
|
|
1116
|
Typhim Vi
|
Typhoid
|
Salmonella typhi
|
Inactivated
|
Sanofi Pasteur SA
|
Approved
|
Intramuscular
|
24599532
|
NA
|
|
1117
|
Typherix
|
Typhoid
|
Salmonella typhi
|
Inactivated
|
GlaxoSmithKline Biologicals
|
Approved
|
Intramuscular
|
24599532
|
NA
|
|
1118
|
Typbar TCV
|
Typhoid
|
Salmonella typhi
|
Conjugate
|
Bharat Biotech
|
Approved
|
Intramuscular
|
NA
|
NA
|
|
1119
|
TYPHIBEV
|
Typhoid
|
Salmonella typhi
|
Conjugate
|
Biological E
|
Approved
|
Intramuscular
|
NA
|
NA
|
|
1120
|
PedaTyph
|
Typhoid
|
Salmonella typhi
|
Conjugate
|
BIO-MED Private Limited
|
Approved
|
Intramuscular
|
NA
|
NA
|
|
1121
|
Zyvac TCV
|
Typhoid
|
Salmonella typhi
|
Conjugate
|
Cadila Healthcare Ltd
|
Approved
|
Intramuscular
|
32134011, 32725225
|
NA
|
|
1122
|
ViVaxim
|
Typhoid
|
Salmonella typhi
|
Combination
|
Sanofi Pasteur Ltd
|
Approved
|
Intramuscular
|
NA
|
NA
|
|
1325
|
TyVEGHA
|
Typhoid
|
Salmonella typhi
|
Conjugate
|
International Vaccine Institute
|
Clinical - Phase 4
|
NA
|
NA
|
NCT04852185
|
|
1326
|
PQed
|
Typhoid
|
Salmonella typhi
|
Conjugate
|
PT Bio Farma
|
Clinical - Phase 3
|
NA
|
NA
|
NCT04051268
|
|
1327
|
Vi-TCV
|
Typhoid
|
Salmonella typhi
|
Conjugate
|
University of Maryland, Baltimore
|
Clinical - Phase 3
|
Intramuscular
|
NA
|
NCT03299426
|
|
1328
|
Vi-DT
|
Typhoid
|
Salmonella typhi
|
Conjugate
|
International Vaccine Institute
|
Clinical - Phase 3
|
Intramuscular
|
NA
|
NCT03933098
|
|
1329
|
Ty800
|
Typhoid
|
Salmonella typhi
|
Live attenuated
|
AVANT Immunotherapeutic
|
Clinical - Phase 2
|
Oral
|
NA
|
NCT00498654
|
|
1330
|
EuTCV
|
Typhoid
|
Salmonella typhi
|
Conjugate
|
EuBiologics Co.,Ltd
|
Clinical - Phase 2, Phase 3
|
Intramuscular
|
NA
|
NCT04830371
|
|
1331
|
M01ZH09
|
Typhoid
|
Salmonella typhi
|
Conjugate
|
University of Oxford
|
Clinical - Phase 2
|
Oral
|
NA
|
NCT01405521
|
|
1332
|
Vi-rEPA
|
Typhoid
|
Salmonella typhi
|
Conjugate
|
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
|
Clinical - Phase 2
|
NA
|
NA
|
NCT00342628
|
|
1333
|
CVD 909
|
Typhoid
|
Salmonella typhi
|
Live attenuated
|
National Institute of Allergy and Infectious Diseases (NIAID)
|
Clinical - Phase 1
|
Oral
|
NA
|
NCT00326443
|
|
1334
|
CVD 908
|
Typhoid
|
Salmonella typhi
|
Live attenuated
|
Centre for Vaccine Development, University of Maryland
|
Clinical - Phase 1
|
Oral
|
17582563
|
NA
|
|
1335
|
CVD 908-HTRA
|
Typhoid
|
Salmonella typhi
|
Live attenuated
|
Evans Medical, Speke
|
Clinical - Phase 2
|
Oral
|
17582563
|
NA
|
|
1336
|
Typhax
|
Typhoid
|
Salmonella typhi
|
Conjugate
|
Matrivax Research and Development Corporation
|
Clinical - Phase 1
|
Intramuscular
|
31905228
|
NCT03926455
|